12:00 AM
 | 
Oct 12, 2015
 |  BC Week In Review  |  Company News  |  Other News

XenoPort neurology, autoimmune news

XenoPort will reduce headcount by 25 (14%) to about 155 and plans to partner XP23829 and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. Cuts include positions related to the XP23829 program. Additionally, Ronald Barrett retired as CEO and director. EVP and COO Vincent Angotti succeeds Barrett. Angotti...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >